Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population

References

• Liu Y, Anders HJ. Lupus nephritis: from pathogenesis to targets for biologic treatment. Nephron Clin Pract. 2014;128(3–4):224–231. doi:10.1159/00036858125401461
   PubMedGoogle Scholar
• Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford, England). 2016;55(2):252–262. doi:10.1093/rheumatology/kev311
   PubMed Web of Science ®Google Scholar
• Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835. doi:10.2215/CJN.0578061627821390
   PubMed Web of Science ®Google Scholar
• Barber MRW, Hanly JG, Su L, et al. Economic evaluation of lupus nephritis in the systemic lupus international collaborating clinics inception cohort using a multistate model approach. Arthritis Care Res (Hoboken). 2018;70(9):1294–1302. doi:10.1002/acr.2348029193883
   PubMed Web of Science ®Google Scholar
• Tucker LB, Uribe AG, Fernandez M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314–322. doi:10.1177/096120330708787518413413
   PubMed Web of Science ®Google Scholar
• Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol. 2015;11(1):46–61. doi:10.1038/nrneph.2014.21525421826
   PubMed Web of Science ®Google Scholar
• Furst DE, Clarke A, Fernandes AW, et al. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population. J Med Econ. 2013;16(4):500–509. doi:10.3111/13696998.2013.77205823363329
   PubMedGoogle Scholar
• Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum. 2009;61(6):755–763. doi:10.1002/art.2454519479688
   PubMed Web of Science ®Google Scholar
• Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin Ther. 2009;31(11):2653–2664. doi:10.1016/j.clinthera.2009.11.03220110008
   PubMed Web of Science ®Google Scholar
• Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH. Quality of care for incident lupus nephritis among medicaid beneficiaries in the United States. Arthritis Care Res (Hoboken). 2014;66(4):617–624. doi:10.1002/acr.2218224124011
   PubMed Web of Science ®Google Scholar
• Yazdany J, Panopalis P, Gillis JZ, et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum. 2009;61(3):370–377. doi:10.1002/art.2435619248127
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon M, Wilkinson A, et al. American college of rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808. doi:10.1002/acr.2166422556106
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European league against rheumatism and European renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782. doi:10.1136/annrheumdis-2012-20194022851469
   PubMed Web of Science ®Google Scholar
• Hanchak NA, Murray JF, Hirsch A, McDermott PD, Schlackman N. USQA health profile database as a tool for health plan quality improvement. Manag Care Q. 1996;4(2):58–69.
   PubMedGoogle Scholar
• Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251. doi:10.1016/0895-4356(94)90129-57722560
   PubMed Web of Science ®Google Scholar
• Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension Prevalence and Control Among Adults: United States, 2015–2016. NCHS Data Brief, No 289. Hyattsville, MD: National Center for Health Statistics; 2017.
   Google Scholar
• Carroll MD, Fryar CD, Nguyen DT. High Total and Low High-Density Lipoprotein Cholesterol in Adults: United States, 2015–2016. NCHS Data Brief, No 290. Hyattsville, MD: National Center for Health Statistics; 2017.
   Google Scholar
• Centers for Disease Control and Prevention. Chronic kidney disease surveillance system—United States. Available from: http://www.cdc.gov/ckd (http://www.cdc.gov/ckd). Accessed 26, 2019.
   Google Scholar
• Xie L, Kariburyo F, Sah J, Lofand J, Li N. Real world medication use in incident systemic lupus erythematosus and lupus nephritis patients [abstract]. Arthritis Rheumatol. 2018;70(suppl 10).
   Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241–250. doi:10.1097/01.ASN.0000108969.21691.5D14747370
   PubMed Web of Science ®Google Scholar
• Rice JB, White AG, Johnson M, et al. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population. J Med Econ. 2018;21(9):846–852. doi:10.1080/13696998.2018.147475029741439
   PubMed Web of Science ®Google Scholar
• Chen SY, Choi CB, Li Q, et al. Glucocorticoid use in patients with systemic lupus erythematosus: association between dose and health care utilization and costs. Arthritis Care Res (Hoboken). 2015;67(8):1086–1094. doi:10.1002/acr.2257425732795
   PubMed Web of Science ®Google Scholar
• Kabadi S, Yeaw J, Bacani AK, et al. Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus. Lupus. 2018;27(11):1799–1809. doi:10.1177/096120331879067530068254
   PubMed Web of Science ®Google Scholar
• Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. doi:10.1136/bmj.j141528404617
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192(2):376–383. doi:10.1016/j.atherosclerosis.2006.05.01916787647
   PubMed Web of Science ®Google Scholar
• Rice JB, White AG, Johnson M, et al. Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population. Curr Med Res Opin. 2018;34(8):1519–1527. doi:10.1080/03007995.2018.147409029741130
   PubMed Web of Science ®Google Scholar
• Shah M, Chaudhari S, McLaughlin TP, et al. Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus. Clin Ther. 2013;35(4):486–497. doi:10.1016/j.clinthera.2013.03.00123587268
   PubMed Web of Science ®Google Scholar